Good morning from the Financial Times.
Today is Tuesday, August 4th, and this is your FT News Briefing.
The boss of Novo Nordisk outlines his deal-making ambitions,
and Russia is preparing a workaround for another set of EU sanctions.
Plus, the US and Japan have banded together to prop up the struggling yen, but why?
It's been nearly 30 years since we've seen anything similar to this, so these things are super, super rare.
I'm Victoria Craig, and here's the news you need to start your day.
Shares of AstraZeneca slid on Monday as investors raised concerns about a potential mega merger with U.S.
Pharmaceutical giant Bristol-Myers Squibb.
That's news the FT broke on Sunday.
Possible risks to the deal include antitrust hurdles and the ultimate value of the deal.
But regardless of what happens, it probably won't be the end of dealmaking in the industry.
And that is because the pair are not the only ones with M&A on their minds.
The FT's Aaron Kirchfeld joins me now.
He recently sat down with the boss of pharma heavyweight Novo Nordisk at the company's headquarters.
Hey, Aaron, welcome back to the show.
Thanks for having me again.
Two days in a row.
Lucky us.
Mike Doostar told you that big mergers and acquisitions are not out of the realm of possibility for his company.